Circulating Tumor DNA in Lymphoma: Principles and Future Directions

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Lymphomas exhibit significant genetic heterogeneity, complicating diagnosis and treatment response assessment.
• Current methods like imaging scans and tissue biopsies have limitations in detecting molecular details and spatial heterogeneity.
• Circulating tumor DNA (ctDNA) presents a minimally invasive alternative for molecular profiling in lymphoma.

Purpose of the Study:

• To review established principles of ctDNA in lymphoma.
• To highlight research questions and future directions for ctDNA application.
• To emphasize ctDNA's potential in aiding clinical decision-making for lymphoma patients.

Main Methods:

• Review of existing literature on ctDNA in lymphoma.
• Analysis of ctDNA's capabilities in providing genotypic information.
• Evaluation of ctDNA's role in assessing minimal residual disease and treatment effectiveness.

Main Results:

• ctDNA is an emerging biomarker for lymphomas, offering non-invasive genotypic insights.
• ctDNA can effectively measure treatment response by detecting minimal residual disease.
• Key principles for ctDNA in lymphoma have been identified.

Conclusions:

• ctDNA shows promise as a versatile biomarker in lymphoma, overcoming limitations of traditional methods.
• Standardization of ctDNA assays and further studies are crucial for establishing its clinical utility.
• ctDNA has the potential to significantly impact lymphoma management and patient outcomes.